Skip to content
10-Q

Quarterly Report

Damora Therapeutics, Inc. DMRA

0001193125-26-219327

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 61.55M sh
Shares Diluted Q1 2026 · Mar 31, 2026 34.3M sh
Shares Diluted Q1 2026 · Mar 31, 2025 1.32M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$20.6M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.44M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $532.9M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $257.62M
Stockholders Equity Q1 2026 · Mar 31, 2026 $511.6M
Stockholders Equity Q1 2026 · Dec 31, 2025 $240.38M
Stockholders Equity Q1 2026 · Mar 31, 2025 $13.71M
Stockholders Equity Q1 2026 · Dec 31, 2024 $15.83M
Current Liabilities Q1 2026 · Mar 31, 2026 $23.81M
Current Liabilities Q1 2026 · Dec 31, 2025 $20.07M
Total Liabilities Q1 2026 · Mar 31, 2026 $23.84M
Total Liabilities Q1 2026 · Dec 31, 2025 $20.15M
Current Assets Q1 2026 · Mar 31, 2026 $535.41M
Current Assets Q1 2026 · Dec 31, 2025 $260.42M
Total Assets Q1 2026 · Mar 31, 2026 $535.44M
Total Assets Q1 2026 · Dec 31, 2025 $260.53M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.62
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.92
Eps Basic Q1 2026 · Mar 31, 2026 −$0.62
Eps Basic Q1 2026 · Mar 31, 2025 −$1.92
Sga Expense Q1 2026 · Mar 31, 2026 $7.03M
Sga Expense Q1 2026 · Mar 31, 2025 $1.92M
Rd Expense Q1 2026 · Mar 31, 2026 $23.78M
Rd Expense Q1 2026 · Mar 31, 2025 $678K
Net Income Q1 2026 · Mar 31, 2026 −$27.78M
Net Income Q1 2026 · Mar 31, 2025 −$2.53M
Operating Income Q1 2026 · Mar 31, 2026 −$30.81M
Operating Income Q1 2026 · Mar 31, 2025 −$2.6M